Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments

Executive Summary

FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization

You may also be interested in...



Phase IV Studies Encounter Delays, Yield Mixed Data – Tufts Report

A survey of 61 post-marketing drug studies conducted by the Tufts Center for the Study of Drug Development concluded that almost half of those trials did not meet their projected completion date. The center released results of the report, which appears in the May/June Tufts CSDD Impact Report, May 15

Phase IV Studies Encounter Delays, Yield Mixed Data – Tufts Report

A survey of 61 post-marketing drug studies conducted by the Tufts Center for the Study of Drug Development concluded that almost half of those trials did not meet their projected completion date. The center released results of the report, which appears in the May/June Tufts CSDD Impact Report, May 15

BioShield Bill Creates “Emergency Use Authority” Tied To Monetary Penalties

FDA could license bioterrorism countermeasures for "emergency use" with the legal backing of monetary penalties to ensure companies comply with the agency's terms under the Senate's "BioShield" bill

Related Content

UsernamePublicRestriction

Register

PS039912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel